📊 ERAS Key Takeaways
Is Erasca, Inc. (ERAS) a Good Investment?
Erasca is a pre-revenue biopharmaceutical company with severe operating losses of $187.9M and negative free cash flow of $27.4M, indicating an estimated 1-2 year cash runway at current burn rates. While the balance sheet shows strong equity positioning and zero debt, the absence of revenue and unsustainable operating burn present fundamental challenges requiring successful clinical advancement or near-term capital raises to avoid dilution or restructuring.
Erasca remains a pre-revenue biotech with no demonstrated commercial revenue base, deeply negative operating income, and substantial ongoing cash burn, which weakens its fundamental profile. The balance sheet is still a meaningful offset, with strong liquidity, no long-term debt, and a large equity cushion, but current fundamentals depend heavily on preserving cash and converting R&D spending into future revenue.
Erasca, Inc. Key Strengths (ERAS)
- Strong balance sheet with $393.5M stockholders' equity and zero long-term debt
- Excellent liquidity ratios (9.52x current ratio) providing runway for operations
- Improving diluted EPS trend (+36.2% YoY) indicating marginal operational efficiency gains
- Strong liquidity with a 10.04x current and quick ratio
- Debt-free balance sheet with 0.00x debt-to-equity
- Solid equity base of $325.17M relative to $70.98M in liabilities
ERAS Stock Risks: Erasca, Inc. Investment Risks
- Pre-revenue stage with no commercial product sales generating cash
- Negative operating cash flow of $27.4M per quarter with limited cash reserves ($47.3M) implying 1-2 year runway
- Substantial operating losses ($187.9M) and negative profitability metrics (ROE -46.6%, ROA -39.8%) with no clear path to profitability without significant clinical/commercial milestones
- No revenue and no gross profit, limiting visibility into business model scalability
- Large operating and free cash flow losses create ongoing funding pressure
- Negative ROE and ROA indicate weak capital efficiency and continued value erosion
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway to next financing event
- Clinical trial progress updates and regulatory pathway advancement
- Insider buying/selling patterns and capital structure changes via equity or debt financing
- Quarterly operating cash burn and ending cash balance
- Any transition from pre-revenue status to meaningful collaboration or product revenue
Erasca, Inc. (ERAS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.52x current ratio provides a solid financial cushion.
ERAS Profit Margin, ROE & Profitability Analysis
ERAS vs Healthcare Sector: How Erasca, Inc. Compares
How Erasca, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Erasca, Inc. Stock Overvalued? ERAS Valuation Analysis 2026
Based on fundamental analysis, Erasca, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Erasca, Inc. Balance Sheet: ERAS Debt, Cash & Liquidity
ERAS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Erasca, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.69 indicates the company is currently unprofitable.
ERAS Revenue Growth, EPS Growth & YoY Performance
Erasca, Inc. Dividends, Buybacks & Capital Allocation
ERAS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Erasca, Inc. (CIK: 0001761918)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ERAS
What is the AI rating for ERAS?
Erasca, Inc. (ERAS) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ERAS's key strengths?
Claude: Strong balance sheet with $393.5M stockholders' equity and zero long-term debt. Excellent liquidity ratios (9.52x current ratio) providing runway for operations. ChatGPT: Strong liquidity with a 10.04x current and quick ratio. Debt-free balance sheet with 0.00x debt-to-equity.
What are the risks of investing in ERAS?
Claude: Pre-revenue stage with no commercial product sales generating cash. Negative operating cash flow of $27.4M per quarter with limited cash reserves ($47.3M) implying 1-2 year runway. ChatGPT: No revenue and no gross profit, limiting visibility into business model scalability. Large operating and free cash flow losses create ongoing funding pressure.
What is ERAS's revenue and growth?
Erasca, Inc. reported revenue of N/A.
Does ERAS pay dividends?
Erasca, Inc. does not currently pay dividends.
Where can I find ERAS SEC filings?
Official SEC filings for Erasca, Inc. (CIK: 0001761918) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ERAS's EPS?
Erasca, Inc. has a diluted EPS of $-0.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ERAS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Erasca, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ERAS stock overvalued or undervalued?
Valuation metrics for ERAS: ROE of -46.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ERAS's AI grade for 2026?
Our dual AI analysis gives Erasca, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ERAS's free cash flow?
Erasca, Inc.'s operating cash flow is $-27.4M, with capital expenditures of $36.0K.
How does ERAS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -46.6% (avg: 15%), current ratio 9.52 (avg: 2).